世界の真性赤血球増加症後骨髄線維症（PPV-MF）市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A15071 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、真性赤血球増加症後骨髄線維症（PPV-MF）のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。真性赤血球増加症後骨髄線維症（PPV-MF）の種類別市場規模（デュルバルマブ、ジビノスタット、グラスデギブ、イデラリシブ、IMG-7289、その他）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・真性赤血球増加症後骨髄線維症（PPV-MF）の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：AbbVie Inc、Celgene Corp、CTI BioPharma Corp、F. Hoffmann-La Roche Ltd、Gilead Sciences Inc、Incyte Corp、Italfarmaco SpA、JW Pharmaceutical Corp、MedImmune LLC、MEI Pharma Inc、Merck & Co Inc、Novartis AG、NS Pharma Inc、Promedior Inc、Sun Pharma Advanced Research Company Ltd ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：デュルバルマブ、ジビノスタット、グラスデギブ、イデラリシブ、IMG-7289、その他 ・用途別分析2016年-2026年：病院、クリニック、その他 ・真性赤血球増加症後骨髄線維症（PPV-MF）の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・真性赤血球増加症後骨髄線維症（PPV-MF）のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・真性赤血球増加症後骨髄線維症（PPV-MF）のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・真性赤血球増加症後骨髄線維症（PPV-MF）の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・真性赤血球増加症後骨髄線維症（PPV-MF）の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Post-Polycythemia Vera Myelofibrosis (PPV-MF) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Post-Polycythemia Vera Myelofibrosis (PPV-MF) market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Durvalumab
Givinostat
Glasdegib
Idelalisib
IMG-7289
Others

Market segment by Application, can be divided into
Hospital
Clinic
Others

Market segment by players, this report covers
AbbVie Inc
Celgene Corp
CTI BioPharma Corp
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
Incyte Corp
Italfarmaco SpA
JW Pharmaceutical Corp
MedImmune LLC
MEI Pharma Inc
Merck & Co Inc
Novartis AG
NS Pharma Inc
Promedior Inc
Sun Pharma Advanced Research Company Ltd

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Post-Polycythemia Vera Myelofibrosis (PPV-MF) product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Post-Polycythemia Vera Myelofibrosis (PPV-MF), with revenue, gross margin and global market share of Post-Polycythemia Vera Myelofibrosis (PPV-MF) from 2019 to 2021.
Chapter 3, the Post-Polycythemia Vera Myelofibrosis (PPV-MF) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Post-Polycythemia Vera Myelofibrosis (PPV-MF) market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Post-Polycythemia Vera Myelofibrosis (PPV-MF) research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Post-Polycythemia Vera Myelofibrosis (PPV-MF)
1.2 Classification of Post-Polycythemia Vera Myelofibrosis (PPV-MF) by Type
1.2.1 Overview: Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Type in 2020
1.2.3 Durvalumab
1.2.4 Givinostat
1.2.5 Glasdegib
1.2.6 Idelalisib
1.2.7 IMG-7289
1.2.8 Others
1.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market by Application
1.3.1 Overview: Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size & Forecast
1.5 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Forecast by Region
1.5.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region, (2016-2021)
1.5.3 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Prospect (2016-2026)
1.5.4 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Prospect (2016-2026)
1.5.6 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Drivers
1.6.2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Restraints
1.6.3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Trends Analysis
2 Company Profiles
2.1 AbbVie Inc
2.1.1 AbbVie Inc Details
2.1.2 AbbVie Inc Major Business
2.1.3 AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
2.1.4 AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 AbbVie Inc Recent Developments and Future Plans
2.2 Celgene Corp
2.2.1 Celgene Corp Details
2.2.2 Celgene Corp Major Business
2.2.3 Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
2.2.4 Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Celgene Corp Recent Developments and Future Plans
2.3 CTI BioPharma Corp
2.3.1 CTI BioPharma Corp Details
2.3.2 CTI BioPharma Corp Major Business
2.3.3 CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
2.3.4 CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 CTI BioPharma Corp Recent Developments and Future Plans
2.4 F. Hoffmann-La Roche Ltd
2.4.1 F. Hoffmann-La Roche Ltd Details
2.4.2 F. Hoffmann-La Roche Ltd Major Business
2.4.3 F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
2.4.4 F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
2.5 Gilead Sciences Inc
2.5.1 Gilead Sciences Inc Details
2.5.2 Gilead Sciences Inc Major Business
2.5.3 Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
2.5.4 Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Gilead Sciences Inc Recent Developments and Future Plans
2.6 Incyte Corp
2.6.1 Incyte Corp Details
2.6.2 Incyte Corp Major Business
2.6.3 Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
2.6.4 Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Incyte Corp Recent Developments and Future Plans
2.7 Italfarmaco SpA
2.7.1 Italfarmaco SpA Details
2.7.2 Italfarmaco SpA Major Business
2.7.3 Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
2.7.4 Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Italfarmaco SpA Recent Developments and Future Plans
2.8 JW Pharmaceutical Corp
2.8.1 JW Pharmaceutical Corp Details
2.8.2 JW Pharmaceutical Corp Major Business
2.8.3 JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
2.8.4 JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 JW Pharmaceutical Corp Recent Developments and Future Plans
2.9 MedImmune LLC
2.9.1 MedImmune LLC Details
2.9.2 MedImmune LLC Major Business
2.9.3 MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
2.9.4 MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 MedImmune LLC Recent Developments and Future Plans
2.10 MEI Pharma Inc
2.10.1 MEI Pharma Inc Details
2.10.2 MEI Pharma Inc Major Business
2.10.3 MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
2.10.4 MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 MEI Pharma Inc Recent Developments and Future Plans
2.11 Merck & Co Inc
2.11.1 Merck & Co Inc Details
2.11.2 Merck & Co Inc Major Business
2.11.3 Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
2.11.4 Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Merck & Co Inc Recent Developments and Future Plans
2.12 Novartis AG
2.12.1 Novartis AG Details
2.12.2 Novartis AG Major Business
2.12.3 Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
2.12.4 Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Novartis AG Recent Developments and Future Plans
2.13 NS Pharma Inc
2.13.1 NS Pharma Inc Details
2.13.2 NS Pharma Inc Major Business
2.13.3 NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
2.13.4 NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 NS Pharma Inc Recent Developments and Future Plans
2.14 Promedior Inc
2.14.1 Promedior Inc Details
2.14.2 Promedior Inc Major Business
2.14.3 Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
2.14.4 Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Promedior Inc Recent Developments and Future Plans
2.15 Sun Pharma Advanced Research Company Ltd
2.15.1 Sun Pharma Advanced Research Company Ltd Details
2.15.2 Sun Pharma Advanced Research Company Ltd Major Business
2.15.3 Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
2.15.4 Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Sun Pharma Advanced Research Company Ltd Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players Market Share
3.2.2 Top 10 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players Market Share
3.2.3 Market Competition Trend
3.3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Market Share by Type (2016-2021)
4.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Application (2016-2021)
5.2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2016-2026)
6.2 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2016-2026)
6.3 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country
6.3.1 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2016-2026)
6.3.2 United States Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Forecast (2016-2026)
6.3.3 Canada Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Forecast (2016-2026)
6.3.4 Mexico Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2016-2026)
7.2 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2016-2026)
7.3 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country
7.3.1 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2016-2026)
7.3.2 Germany Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Forecast (2016-2026)
7.3.3 France Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Forecast (2016-2026)
7.3.5 Russia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Forecast (2016-2026)
7.3.6 Italy Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2016-2026)
8.2 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2016-2026)
8.3 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region
8.3.1 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Region (2016-2026)
8.3.2 China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Forecast (2016-2026)
8.3.3 Japan Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Forecast (2016-2026)
8.3.4 South Korea Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Forecast (2016-2026)
8.3.5 India Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Forecast (2016-2026)
8.3.7 Australia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2016-2026)
9.2 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2016-2026)
9.3 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country
9.3.1 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2016-2026)
9.3.2 Brazil Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Forecast (2016-2026)
9.3.3 Argentina Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2016-2026)
10.2 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2016-2026)
10.3 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country
10.3.1 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2016-2026)
10.3.2 Turkey Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Forecast (2016-2026)
10.3.4 UAE Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million) by Region (2016-2021)
Table 5. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Region (2021-2026)
Table 6. AbbVie Inc Corporate Information, Head Office, and Major Competitors
Table 7. AbbVie Inc Major Business
Table 8. AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
Table 9. AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Celgene Corp Corporate Information, Head Office, and Major Competitors
Table 11. Celgene Corp Major Business
Table 12. Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
Table 13. Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. CTI BioPharma Corp Corporate Information, Head Office, and Major Competitors
Table 15. CTI BioPharma Corp Major Business
Table 16. CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
Table 17. CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. F. Hoffmann-La Roche Ltd Corporate Information, Head Office, and Major Competitors
Table 19. F. Hoffmann-La Roche Ltd Major Business
Table 20. F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
Table 21. F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Gilead Sciences Inc Corporate Information, Head Office, and Major Competitors
Table 23. Gilead Sciences Inc Major Business
Table 24. Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
Table 25. Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Incyte Corp Corporate Information, Head Office, and Major Competitors
Table 27. Incyte Corp Major Business
Table 28. Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
Table 29. Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Italfarmaco SpA Corporate Information, Head Office, and Major Competitors
Table 31. Italfarmaco SpA Major Business
Table 32. Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
Table 33. Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. JW Pharmaceutical Corp Corporate Information, Head Office, and Major Competitors
Table 35. JW Pharmaceutical Corp Major Business
Table 36. JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
Table 37. JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. MedImmune LLC Corporate Information, Head Office, and Major Competitors
Table 39. MedImmune LLC Major Business
Table 40. MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
Table 41. MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. MEI Pharma Inc Corporate Information, Head Office, and Major Competitors
Table 43. MEI Pharma Inc Major Business
Table 44. MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
Table 45. MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Merck & Co Inc Corporate Information, Head Office, and Major Competitors
Table 47. Merck & Co Inc Major Business
Table 48. Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
Table 49. Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 51. Novartis AG Major Business
Table 52. Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
Table 53. Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. NS Pharma Inc Corporate Information, Head Office, and Major Competitors
Table 55. NS Pharma Inc Major Business
Table 56. NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
Table 57. NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Promedior Inc Corporate Information, Head Office, and Major Competitors
Table 59. Promedior Inc Major Business
Table 60. Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
Table 61. Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Sun Pharma Advanced Research Company Ltd Corporate Information, Head Office, and Major Competitors
Table 63. Sun Pharma Advanced Research Company Ltd Major Business
Table 64. Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product and Solutions
Table 65. Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million) by Players (2019-2021)
Table 67. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Players (2019-2021)
Table 68. Breakdown of Post-Polycythemia Vera Myelofibrosis (PPV-MF) by Company Type (Tier 1, Tier 2 and Tier 3)
Table 69. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players Head Office, Products and Services Provided
Table 70. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Mergers & Acquisitions in the Past Five Years
Table 71. Post-Polycythemia Vera Myelofibrosis (PPV-MF) New Entrants and Expansion Plans
Table 72. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million) by Type (2016-2021)
Table 73. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Type (2016-2021)
Table 74. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Forecast by Type (2021-2026)
Table 75. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2016-2021)
Table 76. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Forecast by Application (2021-2026)
Table 77. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2016-2021) & (USD Million)
Table 78. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2026) & (USD Million)
Table 79. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2016-2021) & (USD Million)
Table 80. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2026) & (USD Million)
Table 81. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2016-2021) & (USD Million)
Table 82. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2021-2026) & (USD Million)
Table 83. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2016-2021) & (USD Million)
Table 84. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2026) & (USD Million)
Table 85. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2016-2021) & (USD Million)
Table 86. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2026) & (USD Million)
Table 87. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2016-2021) & (USD Million)
Table 88. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2021-2026) & (USD Million)
Table 89. Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2016-2021) & (USD Million)
Table 90. Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2026) & (USD Million)
Table 91. Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2016-2021) & (USD Million)
Table 92. Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2026) & (USD Million)
Table 93. Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Region (2016-2021) & (USD Million)
Table 94. Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Region (2021-2026) & (USD Million)
Table 95. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2016-2021) & (USD Million)
Table 96. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2026) & (USD Million)
Table 97. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2016-2021) & (USD Million)
Table 98. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2026) & (USD Million)
Table 99. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2016-2021) & (USD Million)
Table 100. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2021-2026) & (USD Million)
Table 101. Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2016-2021) & (USD Million)
Table 102. Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2026) & (USD Million)
Table 103. Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2016-2021) & (USD Million)
Table 104. Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2026) & (USD Million)
Table 105. Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2016-2021) & (USD Million)
Table 106. Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Picture
Figure 2. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Type in 2020
Figure 3. Durvalumab
Figure 4. Givinostat
Figure 5. Glasdegib
Figure 6. Idelalisib
Figure 7. IMG-7289
Figure 8. Others
Figure 9. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Application in 2020
Figure 10. Hospital Picture
Figure 11. Clinic Picture
Figure 12. Others Picture
Figure 13. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 14. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Forecast (2016-2026) & (USD Million)
Figure 15. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Region (2016-2026)
Figure 16. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Region in 2020
Figure 17. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Middle East and Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Drivers
Figure 23. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Restraints
Figure 24. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Trends
Figure 25. AbbVie Inc Recent Developments and Future Plans
Figure 26. Celgene Corp Recent Developments and Future Plans
Figure 27. CTI BioPharma Corp Recent Developments and Future Plans
Figure 28. F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
Figure 29. Gilead Sciences Inc Recent Developments and Future Plans
Figure 30. Incyte Corp Recent Developments and Future Plans
Figure 31. Italfarmaco SpA Recent Developments and Future Plans
Figure 32. JW Pharmaceutical Corp Recent Developments and Future Plans
Figure 33. MedImmune LLC Recent Developments and Future Plans
Figure 34. MEI Pharma Inc Recent Developments and Future Plans
Figure 35. Merck & Co Inc Recent Developments and Future Plans
Figure 36. Novartis AG Recent Developments and Future Plans
Figure 37. NS Pharma Inc Recent Developments and Future Plans
Figure 38. Promedior Inc Recent Developments and Future Plans
Figure 39. Sun Pharma Advanced Research Company Ltd Recent Developments and Future Plans
Figure 40. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Players in 2020
Figure 41. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 42. Global Top 3 Players Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share in 2020
Figure 43. Global Top 10 Players Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share in 2020
Figure 44. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 45. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Type in 2020
Figure 46. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share Forecast by Type (2021-2026)
Figure 47. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Application in 2020
Figure 48. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share Forecast by Application (2021-2026)
Figure 49. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Market Share by Type (2016-2026)
Figure 50. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Market Share by Application (2016-2026)
Figure 51. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Country (2016-2026)
Figure 52. United States Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Canada Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Mexico Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Market Share by Type (2016-2026)
Figure 56. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Market Share by Application (2016-2026)
Figure 57. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Country (2016-2026)
Figure 58. Germany Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. France Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. United Kingdom Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Russia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Italy Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Market Share by Type (2016-2026)
Figure 64. Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Market Share by Application (2016-2026)
Figure 65. Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Region (2016-2026)
Figure 66. China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Japan Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. South Korea Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. India Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Southeast Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Australia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Market Share by Type (2016-2026)
Figure 73. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Market Share by Application (2016-2026)
Figure 74. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Country (2016-2026)
Figure 75. Brazil Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Argentina Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Middle East and Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Market Share by Type (2016-2026)
Figure 78. Middle East and Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales Market Share by Application (2016-2026)
Figure 79. Middle East and Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Country (2016-2026)
Figure 80. Turkey Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. Saudi Arabia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 82. UAE Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 83. Methodology
Figure 84. Research Process and Data Source

---